---
input_text: 'Vaccination management in an asymptomatic child with a novel SCN1A variant
  and family history of status epilepticus following vaccination: A case report on
  a potential new direction in personalised medicine. PURPOSE: SCN1A variants cause
  a spectrum of epilepsy syndromes from Dravet Syndrome, a severe epileptic encephalopathy
  of early infancy to the milder disorder of genetic epilepsy with febrile seizures
  plus (GEFS+). These genetic epilepsies are associated with increased risk of poor
  outcome including complications of status epilepticus and early mortality. Individualised
  management of young children known to be at increased risk should be considered,
  such as around vaccination management. METHODS: We describe two siblings with a
  novel pathogenic SCN1A variant, their management and clinical outcomes following
  routine childhood vaccinations. RESULTS: The index case who had a family history
  of epilepsy of unknown genetic aetiology, died from hypoxic ischemic encephalopathy
  following his 12-month vaccinations, in the context of status epilepticus and enterovirus
  71 infection. The sibling of the index case with the same SCN1A variant was subsequently
  managed with prophylactic regular sodium valproate and additional clobazam post
  vaccination to reduce the risk of seizure. She has successfully completed the childhood
  immunisations to 18 months with no seizures and normal neurodevelopmental progress.
  CONCLUSION: As the aetiology of genetic epilepsies is increasingly known in early
  childhood, opportunities to personalise care, minimise risks and optimise outcomes
  are changing. Further research is needed on the risks and benefits of symptomatic
  and preventative management of seizures around vaccinations in young children with
  genetic epilepsies.'
raw_completion_output: |-
  primary_disease: Genetic epilepsies
  medical_actions: Prophylactic regular sodium valproate administration; Additional clobazam post vaccination
  symptoms: Risk of poor outcome including complications of status epilepticus and early mortality; Hypoxic ischemic encephalopathy; Seizure
  chemicals: Sodium valproate; Clobazam
  action_annotation_relationships: Prophylactic regular sodium valproate administration PREVENTS seizure IN Genetic epilepsies; Additional clobazam post vaccination PREVENTS seizure IN Genetic epilepsies
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Additional clobazam post vaccination PREVENTS seizure IN Genetic epilepsies

  ===

extracted_object:
  primary_disease: Genetic epilepsies
  medical_actions:
    - Prophylactic regular sodium valproate administration
    - Additional clobazam post vaccination
  symptoms:
    - Risk of poor outcome including complications of status epilepticus and early
      mortality
    - Hypoxic ischemic encephalopathy
    - HP:0001250
  chemicals:
    - CHEBI:9925
    - CHEBI:31413
  action_annotation_relationships:
    - subject: Prophylactic regular sodium valproate administration
      predicate: PREVENTS
      object: HP:0001250
      qualifier: Genetic epilepsies
      subject_qualifier: Prophylactic regular
      subject_extension: CHEBI:9925
    - subject: Additional clobazam post vaccination
      predicate: PREVENTS
      object: HP:0001250
      qualifier: Genetic epilepsies
      subject_extension: CHEBI:31413
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
